Keywords: ec, allows, durable, efficacy, data, reyataz, label

EC allows durable efficacy data for Reyataz label

Article | 30 January 2006

Print This

US drug major Bristol-Myers Squibb says that the European Commission has approved the inclusion of 96-week data from clinical study ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in